BridgeBio Oncology Therapeutics Inc. (BBOT) vs CapsoVision, Inc. (CV)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and CapsoVision, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.63HealthcareDelayed quote: Oct 6, 2026, 11:54 AM EDT
CV
CapsoVision, Inc.
$6.48HealthcareDelayed quote: Oct 6, 2026, 11:54 AM EDT
Total return — BBOT vs CV
growth of $100 · dividends reinvested · last 1yBBOT -66.0% (-66.0%/yr)CV +88.3% (+88.3%/yr)CV compounded faster over this window
Log scale — wide-divergence pair
BBOT CV
BBOT vs CV: by the numbers
- •CV is the larger company ($324M vs $291M market cap).
- •Both run net losses; BBOT's is the smaller (0.00% vs -214.74% net margin).
Metrics side by side
Valuation
| Metric | BBOT | CV |
|---|---|---|
| P/S ratio | N/A | 23.30 |
| P/B ratio | 0.90 | 24.59 |
Profitability
| Metric | BBOT | CV |
|---|---|---|
| Gross margin | 0.00% | 50.88% |
| Operating margin | 0.00% | -188.25% |
| Net margin | 0.00% | -214.74% |
| ROE | -56.36% | -226.56% |
| ROIC | -61.10% | -164.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.